back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2023-08-25 17:06 Tx date 2023-08-16 |
$RP
RepliCel Life Sciences Inc. |
Kwok, David
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
150,000 | ||
| Filed 2023-08-25 17:05 Tx date 2023-08-16 |
$RP
RepliCel Life Sciences Inc. |
Kwok, David
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-08-25 17:04 Tx date 2023-08-16 |
$RP
RepliCel Life Sciences Inc. |
Kwok, David
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-05-12 11:24 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Boddington, Gary
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
325,000 | |
| Filed 2023-05-10 17:46 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
780,000 | |
| Filed 2023-05-10 12:23 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
1,155,000 | |
| Filed 2023-05-10 11:57 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Austring, Ben
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+250,000 vol |
670,000 | |
| Filed 2023-05-10 11:53 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$11,250
+75,000 vol $0.15 each |
205,000 | |
| Filed 2023-05-10 11:53 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
650,000 | |
| Filed 2023-05-10 11:43 Tx date 2023-05-08 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+250,000 vol |
600,000 | |
| Filed 2023-03-14 18:16 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$402,150
+2,010,750 vol $0.20 each |
4,861,750 | |
| Filed 2023-03-14 18:16 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$402,150
+4,021,500 vol $0.10 each |
10,034,537 | |
| Filed 2023-03-14 18:14 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$404,250
+2,021,250 vol $0.20 each |
6,744,776 | |
| Filed 2023-03-14 18:13 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$404,250
+4,042,500 vol $0.10 each |
17,401,616 | |
| Filed 2023-03-14 17:10 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
15 - Acquisition or disposition under a prospectus
|
$402,150
+2,010,750 vol $0.20 each |
||
| Filed 2023-03-14 17:10 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
15 - Acquisition or disposition under a prospectus
|
$402,150
+2,010,750 vol $0.20 each |
4,861,750 | |
| Filed 2023-03-14 17:09 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
$402,150
+4,021,500 vol $0.10 each |
10,034,537 | |
| Filed 2023-03-14 17:09 Tx date 2023-03-14 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
$402,150
+4,021,500 vol $0.10 each |
||
| Filed 2023-02-02 20:45 Tx date 2023-02-01 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Holder: Peter W. Lewis Inc. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$1,837
+17,500 vol $0.105 each |
419,077 | |
| Filed 2023-02-01 19:04 Tx date 2023-02-01 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$12,249
+116,666 vol $0.105 each |
13,359,116 | |
| Filed 2023-02-01 19:00 Tx date 2023-02-01 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$1,837
+17,500 vol $0.105 each |
875,632 | |
| Filed 2023-01-30 19:49 Tx date 2021-11-07 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-75,000 vol |
250,000 | |
| Filed 2023-01-30 19:46 Tx date 2023-01-26 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+300,000 vol |
550,000 | |
| Filed 2023-01-30 15:33 Tx date 2023-01-26 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$6,000
+50,000 vol $0.12 each |
130,000 | |
| Filed 2023-01-30 08:40 Tx date 2023-01-26 |
$RP
RepliCel Life Sciences Inc. |
Boddington, Gary
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
250,000 | |
| Filed 2023-01-27 10:09 Tx date 2023-01-26 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+300,000 vol |
680,000 | |
| Filed 2023-01-26 18:02 Tx date 2023-01-26 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+300,000 vol |
655,000 | |
| Filed 2023-01-26 14:44 Tx date 2023-01-26 |
$RP
RepliCel Life Sciences Inc. |
Ma, Simon
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
150,000 | |
| Filed 2023-01-26 14:39 Tx date 2023-01-26 |
$RP
RepliCel Life Sciences Inc. |
Austring, Ben
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+370,000 vol |
420,000 | |
| Filed 2023-01-19 19:46 Tx date 2023-01-17 |
$RP
RepliCel Life Sciences Inc. |
Boddington, Gary
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$19,333
+214,815 vol $0.09 each |
314,815 | |
| Filed 2023-01-19 16:53 Tx date 2023-01-17 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$84,923
+943,596 vol $0.09 each |
13,242,450 | |
| Filed 2023-01-18 11:22 Tx date 2023-01-17 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Holder: Peter W. Lewis Inc. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$26,749
+297,222 vol $0.09 each |
401,577 | |
| Filed 2023-01-18 10:09 Tx date 2023-01-17 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Holder: McElwee Consulting Inc. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$60,374
+670,833 vol $0.09 each |
1,329,245 | |
| Filed 2023-01-18 10:03 Tx date 2023-01-17 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$26,499
+294,444 vol $0.09 each |
1,193,426 | |
| Filed 2023-01-17 17:55 Tx date 2023-01-17 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$37,999
+422,222 vol $0.09 each |
858,132 | |
| Filed 2023-01-05 14:09 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+675,000 vol |
2,851,000 | |
| Filed 2023-01-05 14:08 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$135,000
+1,350,000 vol $0.10 each |
6,013,037 | |
| Filed 2023-01-04 17:27 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Holder: Peter W. Lewis Inc. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$10,000
+100,000 vol $0.10 each |
104,355 | |
| Filed 2023-01-04 17:26 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Holder: Peter W. Lewis Inc. (Indirect Ownership)
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$10,000
+50,000 vol $0.20 each |
50,000 | |
| Filed 2023-01-04 17:23 Tx date 2011-05-27 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Holder: Peter W. Lewis Inc. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-01-04 17:19 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Holder: Peter W. Lewis Inc. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$10,000
+100,000 vol $0.10 each |
||
| Filed 2023-01-03 20:56 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$10,000
+100,000 vol $0.10 each |
||
| Filed 2023-01-03 20:56 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$10,000
+100,000 vol $0.10 each |
307,843 | |
| Filed 2023-01-03 14:20 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+50,200 vol |
50,200 | |
| Filed 2023-01-03 14:20 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-01-03 14:20 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$10,040
+100,400 vol $0.10 each |
898,982 | |
| Filed 2023-01-03 14:09 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Austring, Ben
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
50,000 | ||
| Filed 2023-01-03 14:09 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Austring, Ben
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
320,500 | ||
| Filed 2023-01-03 13:42 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Boddington, Gary
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+50,000 vol |
50,000 | |
| Filed 2023-01-03 13:41 Tx date 2021-06-01 |
$RP
RepliCel Life Sciences Inc. |
Boddington, Gary
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-01-03 13:41 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Boddington, Gary
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$10,000
+100,000 vol $0.10 each |
100,000 | |
| Filed 2023-01-03 12:14 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$621,925
+6,219,250 vol $0.10 each |
12,298,854 | |
| Filed 2023-01-03 12:13 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+3,109,625 vol |
4,723,526 | |
| Filed 2023-01-03 12:10 Tx date 2022-12-30 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
$621,925
+6,219,250 vol $0.10 each |
||
| Filed 2022-09-21 11:18 Tx date 2022-05-04 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$423,233
+1,058,083 vol $0.40 each |
2,176,000 | |
| Filed 2022-09-21 11:17 Tx date 2022-05-04 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
1,117,917 | ||
| Filed 2022-09-21 11:17 Tx date 2022-05-04 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$380,910
+2,116,167 vol $0.18 each |
4,663,037 | |
| Filed 2022-09-21 11:16 Tx date 2022-05-04 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
2,546,870 | ||
| Filed 2022-09-21 11:15 Tx date 2022-05-04 |
$RP
RepliCel Life Sciences Inc. |
Mackay, Jamie
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-05-27 22:22 Tx date 2022-05-04 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+1,051,151 vol |
1,613,901 | |
| Filed 2022-05-27 22:21 Tx date 2022-05-04 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$378,414
+2,102,303 vol $0.18 each |
6,079,604 | |
| Filed 2021-12-17 17:52 Tx date 2021-12-17 |
$RP
RepliCel Life Sciences Inc. |
MainPointe Pharmaceuticals, LLC
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
3,986,687 | ||
| Filed 2021-08-11 12:27 Tx date 2021-08-10 |
$RP
Rockport Capital Corp. |
Guanzon, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$13,333
+133,334 vol $0.10 each |
133,334 | |
| Filed 2021-08-11 12:27 Tx date 2021-06-30 |
$RP
Rockport Capital Corp. |
Guanzon, Robert
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-08-11 12:26 Tx date 2021-08-10 |
$RP
Rockport Capital Corp. |
Londry, John
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$13,333
+133,333 vol $0.10 each |
133,333 | |
| Filed 2021-08-11 12:26 Tx date 2021-06-30 |
$RP
Rockport Capital Corp. |
Londry, John
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-08-11 12:23 Tx date 2021-08-10 |
$RP
Rockport Capital Corp. |
HUNT, CODY
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$13,333
+133,333 vol $0.10 each |
133,333 | |
| Filed 2021-08-11 12:22 Tx date 2021-06-30 |
$RP
Rockport Capital Corp. |
HUNT, CODY
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-08-11 12:22 Tx date 2021-08-10 |
$RP
Rockport Capital Corp. |
CHUNNETT, GORDON
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$20,000
+200,000 vol $0.10 each |
200,000 | |
| Filed 2021-08-11 12:21 Tx date 2021-06-30 |
$RP
Rockport Capital Corp. |
CHUNNETT, GORDON
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-08-11 12:20 Tx date 2021-08-10 |
$RP
Rockport Capital Corp. |
Barr, Harry
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$20,000
+200,000 vol $0.10 each |
200,000 | |
| Filed 2021-08-11 12:20 Tx date 2021-06-30 |
$RP
Rockport Capital Corp. |
Barr, Harry
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-06-18 18:04 Tx date 2021-06-15 |
$RP
RepliCel Life Sciences Inc. |
Boddington, Gary
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+150,000 vol $0.40 each |
150,000 | |
| Filed 2021-06-18 18:04 Tx date 2021-06-01 |
$RP
RepliCel Life Sciences Inc. |
Boddington, Gary
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-06-18 18:03 Tx date 2021-06-01 |
$RP
RepliCel Life Sciences Inc. |
Boddington, Gary
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-06-17 11:57 Tx date 2021-06-15 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$80,000
+200,000 vol $0.40 each |
350,000 | |
| Filed 2021-06-17 11:50 Tx date 2021-06-15 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$130,000
+325,000 vol $0.40 each |
355,000 | |
| Filed 2021-06-17 11:43 Tx date 2021-06-15 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$120,000
+300,000 vol $0.40 each |
380,000 | |
| Filed 2021-06-16 13:46 Tx date 2021-06-15 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$30,000
+75,000 vol $0.40 each |
165,000 | |
| Filed 2021-06-16 13:20 Tx date 2021-06-15 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$30,000
+75,000 vol $0.40 each |
225,000 | |
| Filed 2021-06-16 13:02 Tx date 2021-06-15 |
$RP
RepliCel Life Sciences Inc. |
Ma, Simon
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$20,000
+50,000 vol $0.40 each |
100,000 | |
| Filed 2021-06-16 12:58 Tx date 2021-06-15 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+150,000 vol $0.40 each |
325,000 | |
| Filed 2021-06-16 12:54 Tx date 2021-06-15 |
$RP
RepliCel Life Sciences Inc. |
Buckler, Lee
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$96,000
+240,000 vol $0.40 each |
790,000 | |
| Filed 2021-06-07 18:02 Tx date 2021-06-02 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
$83,426
+216,693 vol $0.385 each |
3,977,301 | |
| Filed 2021-06-03 17:28 Tx date 2021-06-02 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
$8,249
+21,428 vol $0.385 each |
798,582 | |
| Filed 2021-06-03 17:03 Tx date 2021-06-02 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$10,749
+27,922 vol $0.385 each |
207,843 | |
| Filed 2021-06-03 12:40 Tx date 2021-06-02 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Holder: McElwee Consulting Inc. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$18,374
+47,727 vol $0.385 each |
658,412 | |
| Filed 2021-06-03 11:43 Tx date 2021-06-02 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$12,899
+33,506 vol $0.385 each |
435,910 | |
| Filed 2021-06-02 17:23 Tx date 2021-05-27 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Holder: Peter W. Lewis Inc. (Indirect Ownership)
|
Common Shares
11 - Acquisition or disposition carried out privately
|
+4,355 vol |
4,355 | |
| Filed 2021-06-02 17:22 Tx date 2011-05-27 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Holder: Peter W. Lewis Inc. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-05-27 12:56 Tx date 2021-05-17 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$1,633
+4,355 vol $0.375 each |
402,404 | |
| Filed 2021-05-21 22:17 Tx date 2021-05-17 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$5,226
+29,037 vol $0.18 each |
3,760,608 | |
| Filed 2021-05-04 13:32 Tx date 2021-04-30 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$10,749
+27,922 vol $0.385 each |
179,921 | |
| Filed 2021-02-16 20:34 Tx date 2021-02-16 |
$RP
RepliCel Life Sciences Inc. |
Buckler, Lee
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,174
+2,904 vol $0.4043 each |
6,808 | |
| Filed 2021-02-16 20:34 Tx date 2021-02-12 |
$RP
RepliCel Life Sciences Inc. |
Buckler, Lee
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$202.50
+500 vol $0.405 each |
3,904 | |
| Filed 2020-12-01 12:09 Tx date 2020-11-30 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-3,386.46
-16,126 vol $0.21 each |
489,572 | |
| Filed 2020-12-01 12:09 Tx date 2020-10-26 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,250
-15,000 vol $0.15 each |
505,698 | |
| Filed 2020-08-21 11:50 Tx date 2020-08-18 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$128,644
+714,693 vol $0.18 each |
3,731,571 | |
| Filed 2020-08-20 17:56 Tx date 2020-08-18 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$21,498
+119,438 vol $0.18 each |
777,154 | |
| Filed 2020-08-20 10:32 Tx date 2020-08-18 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Holder: McElwee Consulting Inc. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$23,625
+131,250 vol $0.18 each |
610,685 | |
| Filed 2020-08-19 19:57 Tx date 2020-08-18 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$17,249
+95,833 vol $0.18 each |
398,049 | |
| Filed 2020-08-19 15:27 Tx date 2020-08-14 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$13,750
+76,389 vol $0.18 each |
151,999 | |
| Filed 2020-07-30 10:53 Tx date 2020-07-15 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$202,590
+562,750 vol $0.36 each |
562,750 | |
| Filed 2020-07-30 10:52 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-07-30 10:52 Tx date 2020-07-15 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$202,590
+1,125,500 vol $0.18 each |
3,016,878 | |
| Filed 2019-11-22 16:50 Tx date 2019-11-04 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
97 - Other
|
$166,869
+595,963 vol $0.28 each |
1,891,378 | |
| Filed 2019-11-03 01:49 Tx date 2019-10-30 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$9,749
+34,821 vol $0.28 each |
75,610 | |
| Filed 2019-10-29 18:27 Tx date 2019-10-29 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$9,749
+34,821 vol $0.28 each |
657,716 | |
| Filed 2019-10-29 15:22 Tx date 2019-10-29 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$14,249
+50,892 vol $0.28 each |
302,216 | |
| Filed 2019-10-16 12:14 Tx date 2019-09-12 |
$RP
RepliCel Life Sciences Inc. |
Buckler, Lee
5 - Senior Officer of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-15,000 vol |
550,000 | |
| Filed 2019-09-24 12:06 Tx date 2019-09-10 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Convertible Preferred Shares Class A Preference Shares
16 - Acquisition or disposition under a prospectus exemption
|
$100,000
+250,000 vol $0.40 each |
250,000 | |
| Filed 2019-09-24 12:05 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Convertible Preferred Shares Class A Preference Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-09-17 16:28 Tx date 2019-09-13 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Preferred Shares Class A Preference Shares
16 - Acquisition or disposition under a prospectus exemption
|
$15,000
+37,500 vol $0.40 each |
37,500 | |
| Filed 2019-09-17 16:25 Tx date 2010-12-22 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Preferred Shares Class A Preference Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-09-13 10:47 Tx date 2019-09-10 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Holder: Peter W. Lewis Inc. (Indirect Ownership)
|
Convertible Preferred Shares Class A Preference Shares
11 - Acquisition or disposition carried out privately
|
$15,000
+37,500 vol $0.40 each |
37,500 | |
| Filed 2019-09-13 10:45 Tx date 2011-05-27 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Holder: Peter W. Lewis Inc. (Indirect Ownership)
|
Convertible Preferred Shares Class A Preference Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-01-18 Tx date 2017-04-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
-16,129 vol |
15,000 | |
| Filed 2019-01-18 Tx date 2019-01-15 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Holder: McElwee Consulting Inc. (Indirect Ownership)
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$26,249
+55,263 vol $0.475 each |
479,435 | |
| Filed 2019-01-18 Tx date 2019-01-15 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$16,999
+35,789 vol $0.475 each |
40,789 | |
| Filed 2019-01-18 Tx date 2019-01-15 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$36,764
+77,398 vol $0.475 each |
251,324 | |
| Filed 2019-01-18 Tx date 2019-01-15 |
$RP
RepliCel Life Sciences Inc. |
MacKay, Geoffrey
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$27,704
+58,325 vol $0.475 each |
58,325 | |
| Filed 2019-01-18 Tx date 2016-12-07 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
110,000 | |
| Filed 2019-01-18 Tx date 2016-08-10 |
$RP
RepliCel Life Sciences Inc. |
MacKay, Geoffrey
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-135,000 vol |
15,000 | |
| Filed 2019-01-18 Tx date 2017-07-31 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-35,000 vol |
75,000 | |
| Filed 2019-01-18 Tx date 2016-08-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
37 - Stock split or consolidation
|
-280,161 vol |
31,129 | |
| Filed 2019-01-18 Tx date 2015-10-14 |
$RP
RepliCel Life Sciences Inc. |
MacKay, Geoffrey
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-01-18 Tx date 2016-08-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-315,000 vol |
35,000 | |
| Filed 2019-01-18 Tx date 2016-08-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-4,686,280 vol |
520,698 | |
| Filed 2019-01-18 Tx date 2016-12-07 |
$RP
RepliCel Life Sciences Inc. |
MacKay, Geoffrey
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+30,000 vol |
45,000 | |
| Filed 2019-01-17 Tx date 2019-01-15 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$170,000
+357,895 vol $0.475 each |
622,895 | |
| Filed 2019-01-17 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
80,000 | ||
| Filed 2019-01-17 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-01-16 Tx date 2016-12-07 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+30,000 vol |
40,000 | |
| Filed 2019-01-16 Tx date 2018-07-30 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
90,000 | |
| Filed 2019-01-16 Tx date 2016-08-10 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-45,000 vol |
5,000 | |
| Filed 2019-01-16 Tx date 2016-08-10 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-90,000 vol |
10,000 | |
| Filed 2019-01-10 Tx date 2016-08-10 |
$RP
RepliCel Life Sciences Inc. |
Buckler, Lee
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-30,640 vol |
3,404 | |
| Filed 2019-01-10 Tx date 2016-08-10 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-315,000 vol |
35,000 | |
| Filed 2019-01-10 Tx date 2016-08-10 |
$RP
RepliCel Life Sciences Inc. |
Buckler, Lee
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-135,000 vol |
115,000 | |
| Filed 2019-01-10 Tx date 2016-08-10 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Holder: McElwee Consulting Inc. (Indirect Ownership)
|
Common Shares
37 - Stock split or consolidation
|
-3,817,545 vol |
424,172 | |
| Filed 2019-01-10 Tx date 2017-01-07 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
110,000 | |
| Filed 2019-01-10 Tx date 2017-07-31 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-35,000 vol |
75,000 | |
| Filed 2019-01-09 Tx date 2016-12-07 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
75,000 | |
| Filed 2019-01-09 Tx date 2018-07-30 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
175,000 | |
| Filed 2019-01-09 Tx date 2016-08-10 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-1,565,334 vol |
173,926 | |
| Filed 2018-12-18 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
30,000 | ||
| Filed 2018-12-18 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Schutte, Andrew
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,295,415 | ||
| Filed 2018-12-14 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-12-14 Tx date 2018-12-14 |
$RP
RepliCel Life Sciences Inc. |
Lowry, Peter
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
265,000 | ||
| Filed 2018-11-09 Tx date 2018-08-01 |
$RP
RepliCel Life Sciences Inc. |
Ma, Simon
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-108.00
-240 vol $0.45 each |
7,460 | |
| Filed 2018-11-09 Tx date 2017-01-13 |
$RP
RepliCel Life Sciences Inc. |
Ma, Simon
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$14,422
+7,700 vol $1.87 each |
7,700 | |
| Filed 2018-11-09 Tx date 2016-06-13 |
$RP
RepliCel Life Sciences Inc. |
Ma, Simon
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-10-17 Tx date 2018-10-09 |
$RP
RepliCel Life Sciences Inc. |
Yofoto (China) Health Industry Co. Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
1,071,580 | ||
| Filed 2018-10-17 Tx date 2018-10-09 |
$RP
RepliCel Life Sciences Inc. |
Yofoto (China) Health Industry Co. Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
5,357,900 | ||
| Filed 2018-10-02 Tx date 2018-10-01 |
$RP
RepliCel Life Sciences Inc. |
Kordyback, Thomas Albert
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$21,500
+50,000 vol $0.43 each |
200,000 | |
| Filed 2018-08-14 Tx date 2018-07-30 |
$RP
RepliCel Life Sciences Inc. |
Rogers, Hugh
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$21,500
+50,000 vol $0.43 each |
200,000 | |
| Filed 2018-08-14 Tx date 2017-02-03 |
$RP
RepliCel Life Sciences Inc. |
Rogers, Hugh
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$122,999
+75,000 vol $1.64 each |
150,000 | |
| Filed 2018-08-07 Tx date 2018-07-30 |
$RP
RepliCel Life Sciences Inc. |
Buckler, Lee
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+400,000 vol |
700,000 | |
| Filed 2018-08-07 Tx date 2018-07-30 |
$RP
RepliCel Life Sciences Inc. |
Buckler, Lee
5 - Senior Officer of Issuer
Direct Ownership
|
Options
97 - Other
|
-50,000 vol |
300,000 | |
| Filed 2018-08-07 Tx date 2018-07-30 |
$RP
RepliCel Life Sciences Inc. |
Buckler, Lee
5 - Senior Officer of Issuer
Direct Ownership
|
Options
97 - Other
|
-50,000 vol |
350,000 | |
| Filed 2018-08-07 Tx date 2016-12-07 |
$RP
RepliCel Life Sciences Inc. |
Buckler, Lee
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+150,000 vol |
400,000 | |
| Filed 2018-08-07 Tx date 2018-07-30 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$32,250
+75,000 vol $0.43 each |
425,000 | |
| Filed 2018-08-07 Tx date 2018-07-30 |
$RP
RepliCel Life Sciences Inc. |
McElwee, Kevin
3 - 10% Security Holder of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$21,500
+50,000 vol $0.43 each |
||
| Filed 2018-08-07 Tx date 2018-07-30 |
$RP
RepliCel Life Sciences Inc. |
MacKay, Geoffrey
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$21,500
+50,000 vol $0.43 each |
200,000 | |
| Filed 2018-08-07 Tx date 2018-07-30 |
$RP
RepliCel Life Sciences Inc. |
Ma, Simon
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
50,000 | |
| Filed 2018-08-07 Tx date 2016-06-13 |
$RP
RepliCel Life Sciences Inc. |
Ma, Simon
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-08-07 Tx date 2018-08-01 |
$RP
RepliCel Life Sciences Inc. |
Kordyback, Thomas Albert
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
150,000 | |
| Filed 2018-08-07 Tx date 2018-07-30 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$32,250
+75,000 vol $0.43 each |
425,000 | |
| Filed 2018-08-02 Tx date 2018-08-02 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$21,500
+50,000 vol $0.43 each |
80,000 | |
| Filed 2017-02-08 Tx date 2017-02-03 |
$RP
RepliCel Life Sciences Inc. |
Rogers, Hugh
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-02-08 Tx date 2017-02-03 |
$RP
RepliCel Life Sciences Inc. |
Rogers, Hugh
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$122,999
+75,000 vol $1.64 each |
75,000 | |
| Filed 2016-12-29 Tx date 2011-05-27 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-12-29 Tx date 2016-12-29 |
$RP
RepliCel Life Sciences Inc. |
Lewis, Peter Winston
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$18,000
+30,000 vol $0.60 each |
30,000 | |
| Filed 2016-06-02 Tx date 2016-06-01 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$72,000
+480,000 vol $0.15 each |
1,739,260 | |
| Filed 2016-06-02 Tx date 2016-05-31 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-72,000
-900,000 vol $0.08 each |
1,259,260 | |
| Filed 2016-04-06 Tx date 2016-03-31 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-25,000
-125,000 vol $0.20 each |
1,534,260 | |
| Filed 2016-04-06 Tx date 2016-04-05 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$125,000
+625,000 vol $0.20 each |
2,159,260 | |
| Filed 2016-04-06 Tx date 2016-03-31 |
$RP
RepliCel Life Sciences Inc. |
Hall, David M.
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-99,999.90
-740,740 vol $0.135 each |
1,659,260 | |
| Filed 2015-10-15 Tx date 2015-10-14 |
$RP
RepliCel Life Sciences Inc. |
MacKay, Geoffrey
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$54,000
+150,000 vol $0.36 each |
150,000 | |
| Filed 2015-10-15 Tx date 2015-10-14 |
$RP
RepliCel Life Sciences Inc. |
MacKay, Geoffrey
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2015-06-30 Tx date 2013-04-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
53 - Grant of warrants
|
+161,290 vol |
||
| Filed 2015-06-30 Tx date 2013-04-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
53 - Grant of warrants
|
+161,290 vol |
161,290 | |
| Filed 2015-06-30 Tx date 2013-04-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
53 - Grant of warrants
|
+161,290 vol |
||
| Filed 2015-06-29 Tx date 2015-06-25 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
53 - Grant of warrants
|
$76,500
+150,000 vol $0.51 each |
311,290 | |
| Filed 2015-06-29 Tx date 2015-06-25 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$46,500
+150,000 vol $0.31 each |
5,206,978 | |
| Filed 2015-05-12 Tx date 2013-04-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
53 - Grant of warrants
|
+161,290 vol |
||
| Filed 2015-05-12 Tx date 2015-04-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
-161,290 vol |
||
| Filed 2015-05-12 Tx date 2015-04-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
-161,290 vol |
||
| Filed 2015-05-12 Tx date 2013-04-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
53 - Grant of warrants
|
+161,290 vol |
161,290 | |
| Filed 2015-05-12 Tx date 2013-04-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
53 - Grant of warrants
|
$161.29
+161,290 vol $0.001 each |
||
| Filed 2015-05-12 Tx date 2013-04-10 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
53 - Grant of warrants
|
$161.29
+161,290 vol $0.001 each |
||
| Filed 2015-05-12 Tx date 2010-12-22 |
$RP
RepliCel Life Sciences Inc. |
Hoffmann, Rolf
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|